COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,389 Articles (22,816 medRxiv, 8,573 bioRxiv)

Most recent first Previous |  Page 1455: Articles 14541-14550  | Next

Discovery of SARS-CoV-2 Mpro Peptide Inhibitors from Modelling Substrate and Ligand Binding
Chan, H. T. H., Moesser, M. A., Walters, R. K., Malla, T. R., Twidale, R. M., John, T., Deeks, H. M., Johnston-Wood, T., Mikhailov, V., Sessions, R. B., Dawson, W., Salah, E., Lukacik, P., Strain-Damerell, C., Owen, D., Nakajima, T., Swiderek, K., Lodola, A., Moliner, V., Glowacki, D. R., Walsh, M. A., Schofield, C. J., Genovese, L., Shoemark, D., Mulholland, A. J., Duarte, F., Morris, G. M.
10.1101/2021.06.18.446355 — Posted: 2021-06-19
Mapping the host protein interactome of non-coding regions in SARS-CoV-2 genome
Jiang, L., Xiao, M., Liao, Q.-Q., Zheng, L., Li, C., Liu, Y., Yang, B., Ren, A., Jiang, C., Feng, X.-H.
10.1101/2021.06.19.449092 — Posted: 2021-06-19
Sequencing using a two-steps strategy reveals high genetic diversity in the S gene of SARS-CoV-2 after a high transmission period in Tunis, Tunisia.
Fares, W., Ghedira, K., Gdoura, M., Chouikha, A., Haddad-Boubaker, S., Khediri, M., Ayouni, K., Lamari, A., Touzi, H., Hammemi, W., Medeb, Z., Sadraoui, A., Hogga, N., Ben Aleya, N., Triki, H.
10.1101/2021.06.18.449083 — Posted: 2021-06-19
SARS-CoV-2 mRNA Vaccine Induces Robust Specific and Cross-reactive IgG and Unequal Strain-specific Neutralizing Antibodies in Naïve and Previously Infected Recipients
Narowski, T. M., Raphel, K., Adams, L. E., Huang, J., Vielot, N. A., Jadi, R., de Silva, A. M., Baric, R. S., Lafleur, J. E., Premkumar, L.
10.1101/2021.06.19.449100 — Posted: 2021-06-19
Analysis of the Second COVID-19 Wave in India and the United Kingdom Using a Birth-Death Model
Viswanath, N. C.
10.1101/2021.06.16.21259009 — Posted: 2021-06-18
What can we learn from COVID-19 data by using epidemic models with unidentified infectious cases?
Griette, q., Demongeot, J., magal, p.
10.1101/2021.06.16.21259019 — Posted: 2021-06-18
Remdesivir to treat COVID-19: can dosing be optimized?
Conway, J. M., Abel zur Wiesch, P.
10.1101/2021.06.16.21258981 — Posted: 2021-06-18
Benefits of Surveillance Testing and Quarantine in a SARS-CoV-2 Vaccinated Population of Students on a University Campus
Motta, F. C., McGoff, K. A., Deckard, A., Wolfe, C. R., Moody, M. A., Cavanaugh, K., Denny, T. N., Harer, J., Haase, S. B.
10.1101/2021.06.15.21258928 — Posted: 2021-06-18
Massive social protests amid the pandemic in selected Colombian cities: Did they increase COVID-19 cases?
Moreno-Montoya, J., Rodriguez Villamizar, L. A., Idrovo, A. J.
10.1101/2021.06.16.21258989 — Posted: 2021-06-18
Mass mask-wearing notably reduces COVID-19 transmission
Leech, G., Rogers-Smith, C., Sandbrink, J. B., Snodin, B., Zinkov, R., Rader, B., Brownstein, J. S., Gal, Y., Bhatt, S., Sharma, M., Mindermann, S., Brauner, J. M., Aitchison, L.
10.1101/2021.06.16.21258817 — Posted: 2021-06-18 Discussion: Onsite

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).